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Abstract
Background: The secreted proteins from goblet cells compose the intestinal mucus. The aims of this study were to
determine how they exist in two intestinal mucus layers.
Methodology/Principal Findings: The intestinal mucosa was fixed with Carnoy solution and immunostained. Mucus from
the loose layer, the firm layer was gently suctioned or scraped, respectively, lysed in SDS sample buffer with or without DTT,
then subjected to the western blotting of rTFF3, rIgGFccBP or rMuc2. The non-reduced or reduced soluble mucus samples
in RIPA buffer were co-immunoprecipitated to investigate their possible interactions. Polyclonal antibodies for rTFF3, the
rIgGFccBP C-terminal domain and the rMuc2 C-terminal domain confirmed their localization in the mucus layer and in the
mucus collected from the rat intestinal loose layer or firm layer in both western blot and immunoprecipitation experiments.
A complex of rTFF3, which was approximately 250 kDa, and a monomer of 6 kDa were present in both layers of the
intestinal mucus; rIgGFccBP was present in the complex (250–280 kDa) under non-reducing conditions, but shifted to
164 kDa under reducing conditions in both of the layers. rMuc2 was found mainly in a complex of 214–270 kDa under non-
reducing conditions, but it shifted to 140 kDa under reducing conditions. The co-immunoprecipitation experiments showed
that binding occurs among rTFF3, rIgGFccBP and rMuc2 in the RIPA buffer soluble intestinal mucus. Blocking the covalent
interaction by 100 mM DTT in the RIPA buffer soluble intestinal mucus disassociated their binding.
Conclusions/Significance: Rat goblet cell-secreted TFF3, IgGFccBP and Muc2, existing in the two intestinal mucus layers, are
bound together by covalent interactions in the soluble fraction of intestinal mucus and form heteropolymers to be one of
the biochemical mechanisms of composing the net-like structure of mucus.
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Introduction
The gastrointestinal tract is the largest and most exposed surface
in humans and other mammals, and thus, the epithelium is
vulnerable and needs to be protected. The mucous barrier over
the epithelium is important but is often ignored as a research topic.
In particular, an extensive amount of bacteria inhabit the lumen
within the small intestine and colon and live in a mutual
relationship with the host. [1], [2] The disruption of the lumenal
barrier is a feature of common and important gastrointestinal
disorders, which include inflammatory bowel diseases (IBDs). [3],
[4], [5]
The colonic mucus is composed of two different layers: the outer
layer is the loose layer and is easy to remove, and the inner layer is
a firm layer, which is strongly attached to the epithelium and must
be removed by scraping. [6] A recent study has revealed that the
inner layer of mucus is devoid of bacteria and that the bacteria
only reside within the loose layer of mucus. [7] Mucus is a highly
viscous and elastic barrier that protects the mucosal surfaces by
selectively trapping and shedding pathogens, toxins, and ultrafine
particles, while allowing the rapid flux of nutrients, antibodies, and
cells of the mucosal immune system.
Mucin 2 (MUC2), trefoil factor 3 (TFF3) and IgGFc gamma
binding protein (IgGFccBP) are the main proteins secreted from
goblet cells. TFF3 has been implicated in multiple mucosal
protection and repair processes, where it plays a key role in the
integrity of the mucous epithelia. [8] It is clear that only the
luminal application, but not the systemic delivery, of recombinant
TFF3, is protective in colitis models; [9] however, its exact
mechanism is unclear, and it is consistent with the lack of
characterization of specific receptor of TFF3, to date. [10] It is
important to understand the biochemical role of TFF3 in the
maintenance of the intestinal mucus, although the existing reports
are controversial. Hansson et al. reported that TFF3 was not
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study, [11] but human TFF3 does form disulfide-linked hetero-
dimers with the mucus-associated FCGBP protein, and the
intestinal mucus was shown to be a reservoir for TFF3. [12]
Therefore, it is necessary to explore the potential role of TFF3 in
maintaining the viscosity and elasticity of the intestinal mucus.
The IgGFccBP protein is a mucin that has received little
attention; it binds only to the Fc portion of IgG, not to IgG Fab,
IgA, or IgM. [13] It has been suggested that the human IgGFccBP
protein is secreted from goblet cells and that some of the
IgGFccBP protein can be secreted into the circulatory system by
an unknown mechanism in patients with autoimmune disease.
[14] We previously reported that the rat IgGFccBP protein was
depleted during dextran sulfate sodium (DSS)-induced colitis. [15]
Furthermore, proteomic analyses of the intestinal mucus revealed
that the IgGFccBP protein was one of the important components
of mucus and that there was an interaction in the insoluble, firm
layer mucus between the human IgGFccBP protein and MUC2
[11] as well as between the IgGFccBP protein and TFF3. [12]
Thus, it is necessary to explore how the IgGFccBP protein takes
part in the formation and organization of the mucus network as
well as its inherent function.
MUC2 is the predominant mucin expressed in the intestine of
humans, rats and mice, and MUC2 mucin monomers form dimers
in the endoplasmic reticulum via intermolecular disulfide bonds
between its carboxy (C)-terminal cysteine knot domains. [16], [17]
The MUC2 mucin is the major structural component of the
colonic mucus gel. Their N- and C-terminal cysteine-rich domains
are involved in mucin polymerization. The Entamoeba histolytica
cysteine proteases can cleave the C-terminal domain of MUC2 to
disrupt the protective mucus barrier. [18] The mechanical
properties of biopolymer networks of the intestinal mucus are
helpful to understand its physiological significance and the
pathophysiological involvement in a series of bowel diseases.
Based on polyclonal antibodies against rat TFF3, the IgGFccBP
C-terminal domain and the Muc2 C-terminal domain, in this
report, we investigated the distribution of rTFF3, rIgGFccBP and
rMuc2 in the two intestinal mucus layers and the mucosa, their
existing molecular patterns (especially in the two mucus layers)
under reduced or non-reduced conditions, and their potential
binding in the mucus layer.
Results
The collection of the mucus from the loose or firm layers
of rat intestine
The intact mucosa with two mucus layers, the suctioned mucosa
with only firm mucus layer and the scraped mucosa without two
mucus layers were fixed using Carnoy solution and stained by
Alcian blue-periodic acid Schiff (AB/PAS) method. As shown in
Figure 1A, there were two mucus layers above the intestinal
epithelium: the top layer (arrowhead) of mucus appeared loose,
and the low layer (arrow) of mucus appeared to be lamellar. After
suction of the loose layer of mucus, the firm layer remained
(Figure 1B); the intestinal mucosa without the firm layer of mucus
was left after scraping of firm mucus layer (Figure 1C). Thus, the
collection method of the loose layer or firm layer of the intestinal
mucus was facilitated for the following experiments.
The presence of rTFF3, rIgGFccBP and rMuc2 in the
mucus layers by immunohistochemistry
To confirm their presence of rTFF3, rIgGFccBP and rMuc2 at
themucuslayerandtodetermineanydifferenceintheirdistribution
between the loose and firm layers, an immunohistochemical
staining of the rat intestinal mucosa, fixed with the Carnoy solution,
was carried out with anti-rTFF3, anti-rIgGFccBP and anti-rMuc2
polyclonal antibodies. As shown in Figures 2A, rTFF3 was present
in the two intestinal mucus layers and the goblet cells within the
mucosa. The immunostaining of rIgGFccBP (Figures 2B) and
rMuc2 (Figures 2C) revealed that both were present in the goblet
cells within the mucosa and two intestinal mucus layers. They were
distributed evenly in the loose and firm layers, with no significant
difference between them.
rTFF3 in the loose and firm mucus layers and the mucosa
without the two layers under reduced and non-reduced
conditions
To discriminate a possible difference in the rTFF3 distribution
between the loose and firm mucus layers and the mucosa without
two mucus layers, we investigated the presence of rTFF3 in the
mucus from the loose or firm mucus layers and the mucosa
without the two mucus layers under reduced and non-reduced
conditions using sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and western blotting. As shown in
panel A of Figure 3, under non-reducing conditions, rTFF3 was
present in the loose layer mucus, mainly in the form of complex
with a molecular weight of 250 kDa, and a small amount was
present, presumably as a monomer, with a molecular weight of
6 kDa (lane 1); under reducing conditions, all of the rTFF3
identified was at a molecular weight of 6 kDa (lane 2). Similarly,
rTFF3 was present in the firm layer mucus and mucosa without
two mucus layers, where it was found mainly in the form of a
complex (250 kDa) and a small amount of monomer (6 kDa)
under the non-reduced conditions (lanes 3 and 5) and a monomer
(6 kDa) under the reduced conditions (lanes 4 and 6). Although the
immunoreactivity of rTFF3 among the loose mucus layer, firm
mucus layer and mucosa without two mucus layers was not same,
the molecular pattern of rTFF3 among them was similar. This
finding indicates that rTFF3 was complexed with an unknown
protein(s) in the goblet cells within the mucosa and that this
complex was secreted into the firm mucus layer until the formation
of the loose mucus layer.
rIgGFccBP in the loose and firm mucus layers and the
mucosa without the two layers under reduced and non-
reduced conditions
T od i s c r i m i n a t et h ep o s s i b l ed i f f e r e n c eo fr I g G F c cBP
distribution between the loose mucus layer, firm mucus layer
and mucosa without two mucus layers, the presence of
rIgGFccBP was determined in the mucus from the loose and
firm mucus layers and the mucosa without the two mucus layers
under reducing and non-reducing conditions using SDS-PAGE
and western blotting. As shown in panel B of Figure 3,
rIgGFccBP was present in the loose layer mucus, mainly in the
form of a complex with a molecular weight of 250–280 kDa
under the non-reducing conditions (lane 1); however, under
reducing conditions, rIgGFccBP was mainly present at a
molecular weight of 164 kDa (lane 2). As with the loose mucus
layer, rIgGFccBP was also present in the firm layer mucus and
the mucosa without the two mucus layers, mainly in the form of
a complex (250–280 kDa) under non-reduced conditions (lanes
3 and 5), and rIgGFccBP existed as a monomer (164 kDa)
under reduced conditions (lanes 4 and 6). This results indicate
that rIgGFccBP was complexed with an unknown protein(s) in
the goblet cells within the mucosa and that this complex was
secreted into the firm mucus layer until the formation of the
loose mucus layer.
Rodent TFF3, IgGFccBP and Muc2 in Mucus Layer
PLoS ONE | www.plosone.org 2 May 2011 | Volume 6 | Issue 5 | e20334rMuc2 in the loose and firm mucus layers and the
mucosa without the two layers under reduced and
non-reduced conditions
To discriminate the possible difference of rMuc2 distribution
between the loose mucus layer, firm mucus layer and mucosa
without two mucus layers, the presence of rIgGFccBP was
determined in the mucus from the loose and firm mucus layers
and the mucosa without the two mucus layers under reducing and
non-reducing conditions using SDS-PAGE and western blotting.
As shown in panel C of Figure 3, under non-reducing conditions,
rMuc2 was present in the loose layer mucus, mainly in the form of
a complex with a molecular weight of 214–270 kDa (lane 1),
whereas under reducing conditions, rMuc2 was mainly present at
a molecular weight of 140 kDa (lane 2). rMuc2 was also present in
the firm layer mucus and mucosa without two mucus layers,
mainly in the form of a complex (more than 214 kDa) under non-
reducing conditions (lanes 3 and 5). We found that rMuc2 existed
as a monomer (140 kDa) under reducing conditions (lanes 4 and
6). As with the other two proteins, this finding indicates that
rMuc2 was complexed with an unknown protein(s) in the goblet
cells within the mucosa and that this complex was secreted into the
firm mucus layer until the formation of the loose mucus layer.
The immunoprecipitation of rTFF3, rIgGFccBP or rMuc2
with anti-rTFF3, anti-rIgGFccBP or anti-rMuc2 polyclonal
antibodies in the intestinal mucus
To confirm the specificity of the anti-rTFF3, anti-rIgGFccBP or
anti-rMuc2 polyclonal antibodies used in the following immuno-
precipitation experiment, we used the anti-rTFF3, anti-
rIgGFccBP or anti-rMuc2 polyclonal antibodies to immunopre-
cipitate the reduced intestinal mucus, which included the loose
layer and firm layer. As shown in Figure 4, when the reduced
mucus was immunoprecipitated with anti-rIgGFccBP polyclonal
serum or preimmune serum, and detected with anti-rIgGFccBP
polyclonal serum or preimmune serum, a 164 kDa polypeptide
could be detected with the anti-rIgGFccBP polyclonal serum in
the mucus immunoprecipitated by the anti-rIgGFccBP polyclonal
serum, but not in the mucus immunoprecipitated by the
preimmune serum. However, there was no positive polypeptide
found in the mucus immunoprecipitated by preimmune serum
Figure 1. Micrographs of rat intestinal mucosa of the colon fixed with Carnoy solution and stained by AB/PAS staining method
(original magnification 6400). Normal colonic mucosa contained two mucus layers, the top, loose layer of mucus (arrowhead) and a stratified,
firm layer of mucus (arrow) (A); the colonic mucosa after suction of the mucus contained only the stratified firm layer of mucus (arrow) (B); the colonic
mucosa after suction and scraping of the mucus (C).
doi:10.1371/journal.pone.0020334.g001
Figure 2. Immunohistochemical staining of the rat intestinal mucosa fixed with Carnoy solution (original magnification 6400). Rat
TFF3 (A), IgGFccBP (B) and Muc2 (C) existed in the two mucus layers and goblet cells.
doi:10.1371/journal.pone.0020334.g002
Rodent TFF3, IgGFccBP and Muc2 in Mucus Layer
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preimmune serum. This result indicates that the anti-rIgGFccBP
polyclonal serum produced in the study was suitable for the
immunoprecipitation experiment. The same experiment using
anti-TFF3 or anti-Muc2 polyclonal serum also confirmed that
both of these polyclonal antibodies were suitable for the
immunoprecipitation experiment.
The confirmation of the binding of rTFF3, rIgGFccBP and
rMuc2 in the intestinal mucus by a co-
immunoprecipitation experiment
The non-reduced mucus from rat intestine was collected from
the fresh intestine of the sacrificed rat and contained not only the
loose layer but also the firm layer; the sample was immunopre-
cipitated with anti-rTFF3, anti-rIgGFccBP or anti-rMuc2 poly-
clonal antibodies, separated by SDS-PAGE and detected by anti-
rTFF3, anti-rIgGFccBP or anti-rMuc2 polyclonal antibodies. As
shown in Figure 5A, in the immunoprecipitates using the anti-
TFF3 polyclonal antibody, a 6 kDa product was detected using
anti-rTFF3, anti-rIgGFccBP and anti-rMuc2 polyclonal antibod-
ies, but it was not detected in the immunoprecipitates using pre-
immune serum. In the immunoprecipitates using the anti-
rIgGFccBP polyclonal antibody, a 164 kDa product was detected
using the anti-rTFF3, anti-rIgGFccBP and anti-rMuc2 polyclonal
antibodies, but the result was negative in the immunoprecipitates
using pre-immune serum. In the immunoprecipitates using the
anti-rMuc2 polyclonal antibody, a 164 kDa product was detected
with the anti-rTFF3, anti-rIgGFccBP and anti-rMuc2 polyclonal
antibodies, but no such product was detected in the immunopre-
cipitates using pre-immune serum. Thus, the results indicate that
rTFF3, rIgGFccBP and rMuc2 in the rodent intestinal mucus
were associated with each other when the sample was processed
under the non-reducing conditions.
The disruption of covalent interactions by dithiothreitol
(DTT) disassociates the binding among rTFF3, rIgGFccBP
and rMuc2
The fresh mucus collected from rat intestine containing the
loose layer and firm layer were dissolved in RIPA lysis buffer
(RIPA) with 100 mM DTT, and the reduced sample was
immunoprecipitated with anti-rTFF3, anti-rIgGFccBP or anti-
rMuc2 polyclonal antibodies, separated by SDS-PAGE and
detected by anti-rTFF3, anti-rIgGFccBP and anti-rMuc2 poly-
clonal antibodies. As shown in Figure 5B, in the immunoprecip-
itates using the anti-TFF3 polyclonal antibody, a 6 kDa product
was detected using only the anti-rTFF3 polyclonal antibody, but
not detected using either anti-rIgGFccBP or anti-rMuc2 poly-
clonal antibodies. In the immunoprecipitates using the anti-rMuc2
polyclonal antibody, a 140 kDa product was detected only using
the anti-rMuc2 polyclonal antibody, but not detected using either
Figure 3. Rat TFF3 (panel A), IgGFccBP (panel B) and Muc2
(panel C) in the loose (L) and firm (F) mucus layers and mucosa
free of mucus (M) under reduced (r) and non-reduced (n-r)
conditions.
doi:10.1371/journal.pone.0020334.g003
Figure 4. Immunoprecipitation of rat TFF3 (panel C), IgGFccBP
(panel A) or Muc2 (panel B) in the intestinal mucus with the
corresponding antibodies. 6 kDa, 164 kDa or 140 kDa proteins were
identified with their respective antibodies, but not with their
preimmune serum, in the reduced intestinal mucus dissolved in RIPA
buffer.
doi:10.1371/journal.pone.0020334.g004
Figure 5. Coimmunoprecipitation of rat TFF3, IgGFccBP or
Muc2 in the non-reduced (A) and reduced (B) intestinal mucus
and blotted with each antibody. 6 kDa proteins were detected with
the anti-rTFF3 antibody in the immunoprecipitates with anti-rTFF3, anti-
rIgGFccBP and anti-Muc2 antibodies. 164 kDa proteins were detected
with the anti-rIgGFccBP antibody in the immunoprecipitates with anti-
rTFF3, anti-rIgGFccBP and anti-rMuc2 antibodies. The 140 kDa proteins
were detected with the anti-rMuc2 antibody in the immunoprecipitates
with anti-rTFF3, anti-rIgGFccBP and anti-rMuc2 antibodies.
doi:10.1371/journal.pone.0020334.g005
Rodent TFF3, IgGFccBP and Muc2 in Mucus Layer
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immunoprecipitates using the anti-rIgGFccBP polyclonal anti-
body, a 164 kDa product was detected only using the anti-
rIgGFccBP polyclonal antibody, but not detected using either
anti-rTFF3 or anti-rMuc2 polyclonal antibodies. This result
suggests that the interactions among rTFF3, rIgGFccBP and
rMuc2 in the rodent intestinal mucus are based on covalent bonds,
which were disrupted by DTT.
Discussion
It has long been known that the intestinal mucus layers of the
colon are an important defense barrier against bacteria and other
toxic factors. Researchers have begun exploring these interactions
to gain a deeper understanding of the organization of the mucus
layer and the molecular details of its main components. [19]
Indeed, a better insight into the biochemical nature of the mucus
layer of colon is fundamental for an understanding of how this
protective function is achieved. The groups of Holm and
Hansson have identified a method for measuring the thickness
of the two mucus layers, and they have performed a detailed
proteomic analysis of the two colonic mucus layers. [6], [20]
MUC2 and IgGFccBP were identified as two of the main
proteins present in the two mucus layers. [11] Although a binding
between human MUC2 and IgGFccBP and human TFF3 and
IgGFccBP in the intestinal mucus layers was determined based
on proteomic analyses. [11], [12] It has not been confirmed by
other methods, including co-immunoprecipitation experiments,
until now.
Rat IgGFccBP is composed of 2583 amino acids (NM_
001164657.1), in which there are 5 potential autoproteolytic
cleavage sites (GDPH) [21], [22] and the 11 tandem repeats. The
epitope of CGKIRDPKGPFATC, which was recognized by the
anti-rIgGFccBP antibody, is located in the C-terminal region of
rIgGFccBP. If proteolysis occurs at the last predicted GDPH site,
the resulting C-terminal domain of IgGFccBP would be 926
residues long. We have confirmed previously that it was depleted
in the animal model of DSS-induced colitis and expressed in the
epithelium of immature intestinal mucosa, [15] and that it is
distributed in various mucin-producing cells, is present in body
fluids, and can be found in the serum of some autoimmune
diseases. [13], [23] Although IgGFccBP can bind to the Fc portion
of IgG, the biological function of rat IgGFccBP has remained
unclear, due to the lack of a potential antibody against rat
IgGFccBP. The presence of the sequence of repetitive vWD
domains may indicate additional functions, as suggested for the
molecules of other mucins, in which the vWD domains are
involved in oligomerization. Our present data provided a direct
evidence for the covalent interaction of the C-terminal domain of
rat IgGFccBP with both the C-terminal domain of rMuc2 and
TFF3.
The facilitation of the homodimer formation via the C-terminal
domain of rMuc2 has been previously reported [16] In the present
study, we confirmed that the C-terminal domain of rMuc2 can
form a heteropolymer with the C-terminal domain of rat
IgGFccBP and rTFF3 in the soluble mucus through covalent
interactions. In agreement with the findings by Hansson’s group,
the human MUC2 and mouse Muc2 bound to the N-terminal
regions of IgGFccBP in the insoluble mucus via covalent
interaction. Whereas the N-terminal regions of IgGFccBP bind
to human MUC2 and mouse Muc2, the C-terminal domain of
IgGFccBP binds to rat Muc2 and rat TFF3; it is conceivable that
the heteropolymers formed might be responsible for the nature of
the net-like, disulfide bond-based structures of the intestinal
mucus. It is clear that the rigid structure of the intestinal mucus in
the firm layer of mucus provides an important barrier, preventing
the infiltration of bacteria, and that the loose layer is the result of
the inflation of the firm mucus layer when there is a large load of
bacteria. [24]
In the report of Hansson, their proteomic analysis did not
include human or mouse TFF3 in the two intestinal mucous layers.
TFF3 possesses a broad range of activity, including the
modification of epithelial growth, cell motility, and acid secretion.
[25], [26] However, there is a lack of identification of their
putative receptors. Whether TFF3 exerts a potential role in
maintaining the net-like, disulfide bond-based structures of the
intestinal mucus is not well understood. Hoffmann’s group has
isolated TFF3 from human colonic extracts under non-reducing
conditions and purified a TFF3 heterodimer; after characteriza-
tion by LC-ESI-MS/MS analysis, they confirmed that TFF3
bound to IgGFccBP via a disulfide bond, which could be disrupted
by hydrogen sulfide. [12]
The major result of our present study indicated that rat TFF3,
the rat Muc2 C-terminal domain and the rat IgGFccBP C-
terminal domain undergo disulfide bond-based interactions in the
RIPA buffer soluble fragments of two mucous layers and
suggesting one of the biochemical basis of the net-like structures
of intestinal mucus. The data provide a better insight into the
biochemical nature and organization of the rat intestinal mucus
layer, which will be fundamental for an understanding of how this
protective function of the rat intestinal mucus layer is constructed
and of how this mechanism might relate to the pathophysiology of
intestinal diseases, such as IBD, infection of the intestine and
intestinal carcinoma. [27] Although GuHCl extraction of the
intestinal mucus is the traditional method to dissociate non-
covalent bonds and maintain covalent interactions, the lysis of the
intestinal mucus using RIPA buffer can also maintain the covalent
interaction between molecules and is suitable for the detection of
interactions between proteins.
The possible biological functions of the heteropolymer among
the rTFF3-rMuc2 C-terminal domain-rIgGFccBP C-terminal
domain for the structure of the rat intestinal mucus are unknown.
rMuc2 and rIgGFccBP are two major components of the intestinal
mucus and provide the characteristics of the intestinal mucus
barrier. rTFF3 might exert an extra function to strengthen the
intestinal mucus barrier.
The weakness of present study is that we only confirmed the
binding among the rTFF3-rMuc2 C-terminal domain-rIgGFccBP
C-terminal domain in the RIPA buffer soluble fraction of rat
intestinal mucus, in which represents a small amount of the
intestinal mucus components. It is still unclear whether there is a
similar binding among the rTFF3-rMuc2 C-terminal domain-
rIgGFccBP C-terminal domain in the insoluble fraction of rat
intestinal mucus due to the technical limitations of immunopre-
cipitation experiments.
Materials and Methods
Materials
Eight-week-old, specified pathogen-free Wistar rats (purchased
from the Animal Facility, Third Military Medical University,
Chongqing, China) were housed at a constant temperature and
humidity on a 12-hour light/dark cycle. One week before and
during the experiment, the rats were housed individually. The rats
had free access to a standard pelleted diet and sterilized tap water.
All experiments were performed with the approval of the Animal
Studies Ethics Committee of Southwest Hospital, Third Military
Medical University(permit number: sw20070612).
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antibodies
The produce and characterization of the anti-rTFF3, anti-
rIgGFccBP or anti-rMuc2 polyclonal antibodies was described
previously. [15], [16], [28], [29], [30], [31], [32] The anti-rMuc2
polyclonal antibody was raised using ‘d-link’, a deglycosylated
118 kDa glycoprotein in New Zealand rabbits and the anti-rMuc2
polyclonal antibody was strongly reactive to the synthetic peptide,
DEWLVNDPSKPHC. The anti-rTFF3 polyclonal antibody was
raised using a 21-residue peptide-keyhole limpet hemocyanin
(KLH) (QEFVGLSPSQCMAPTNNRVDC) and the anti-
rIgGFccBP polyclonal antibody was raised using a 14-residue
peptide (CGKIRDPKGPFATC)-KLH.
Immunostaining
Segments of the distal rat colon were fixed in water-free
Methanol-Carnoy’s fixative (60% methanol, 30% chloroform and
10% acetic acid). The tissues were washed in methanol before
being embedded in paraffin and sectioned (5 mm). The sections
were dewaxed using Xylene Substitute and then hydrated. The
antigens were retrieved by microwave heating in 0.01 M citric
buffer (pH 6), and the sections were stained with anti-rTFF3
(1:100), anti-rIgGFccBP (1:100) or anti-rMuc2 (1:200) polyclonal
antibodies. FITC-conjugated goat anti-rabbit immunoglobulin
was used as secondary antibodies (Boster Biological Technology
Co. LTD., Wuhan, P. R. of China), and the DNA was stained with
DAPI (Invitrogen, Carlsbad, CA, USA). The images were
obtained using a BX51 (Olympus, Tokyo, Japan) fluorescence
microscope. The negative controls, using unrelated anti-serum or
PBS buffer for the first antibodies, were used to determine the
specificity.
Histological staining
A combined method, utilizing the properties of both the PAS
and Alcian blue methods, to demonstrate that the full complement
of tissue proteoglycans was employed. Last, the nuclei were stained
with hematoxylin for 1 minute, and the sections were dehydrated,
cleared and mounted.
Collection of the mucus from the loose layer or firm layer
of rat intestine
Wistar rats from the Animal Facility, Third Military Medical
University, Chongqing, China, were fasted for 24 hours before
euthanasia. The colon was separated and dissected between the
cecum, which was 5 cm distant from the beginning of cecum, and
the rectum, which was 2 cm distant from the end of rectum, and
cut longitudinally and immediately spread on a smooth and stiff
cardboard; the mucus from a dissected 1.5 cm rat colon was
collected by suction (loosely adherent). After suction, the mucus
from the firm layer of the intestinal mucus layer was scraped
(firmly adherent). The remaining mucosa, free of the mucus, was
scraped and homogenized for further experiments. A complete,
EDTA-free protease inhibitor (Roche Molecular Diagnostics,
4300 Hacienda Drive, Pleasanton, CA 94588 USA) was added
to the samples of mucus from the loose layer, firm layer and
mucosa (free of mucus).
SDS-PAGE and western blotting analysis
The collected samples of the loose-layer mucus, firm-layer
mucus or homogenized intestinal mucosa, free of mucus, were
lysed in SDS sample buffer. The samples were divided, and one
was reduced in sample buffer with 100 Mm DTT, while the other
was not reduced (as a control); the samples were subjected to SDS-
PAGE (12%) after heating for 5 minutes in boiling water. The
proteins were then transferred to an Immobilon P membrane. The
membranes were blocked for 1 hour in 5% nonfat dry milk in
TBST (TBS containing 0.05% Tween-20) and hybridized at 4uC
overnight in TBST with the primary antibodies (anti-rTFF3,
1:500, anti-rIgGFccBP, 1:800, or anti-rMuc2, 1:3000). The
membranes were washed three times in PBST, for 5 min each
time, and the secondary detection was done using 1:12,000
dilutions of HRP-conjugated goat anti-rabbit antibody. The
membranes were then washed three times, for 10 min each. The
blots were processed either with the SuperSignalH West Pico
Chemiluminescent Substrate, and the signal was detected by
exposing X-ray films to the processed blots. SeeBlueH Plus2 was
used as the reference sample of molecular mass standards.
Immunoprecipitation of rTFF3, rIgGFccBP or rMuc2 in the
intestinal mucus
The freshly collected rat intestinal mucus, including the loose
layer and firm layer, was lysed in 5 volumes of RIPA buffer, and a
complete, EDTA-free protease inhibitor (Roche) was added.
After mixing for 2 hours at 4uC, the samples were centrifuged at
100006g for 10 minutes, and the soluble supernatant was
collected and precleared with 50 ml protein-G agarose. But the
insoluble pellet which contained a large proportion of the Muc2
mucus was discarded, as the insoluble pellet was not suitable for
the immunoprecipitation experiment. The specific proteins were
immunoprecipitated during a 16 h incubation at 4uCw i t ha n t i -
rTFF3, anti-rIgGFccBP, anti-rMuc2 serum or their preimmune
sera in the presence of 50 ml protein-G agarose. The immuno-
precipitates were washed twice in RIPA buffer (50 mM Tris/HCl
[pH 7.5], 150 mM NaCl, 1% (v/v) Nonidet P40 (NP40), 0.5%
Sodium deoxycholate, 0.1% SDS and protease inhibitor) and
once in 10 mM Tris/HCl buffer (pH 7.4) containing 0.1% NP40
and then were subjected to SDS/PAGE after reduction with
100 mM DTT; then, the proteins were transferred to an
Immobilon P membrane, the separated proteins were blotted
with anti rTFF3, anti-rIgGFccBP, anti-rMuc2 serum or their
preimmune serum. The further experiment was performed as
described previously.
Co-immunoprecipitation experiment
The non-reduced mucus from the rat intestine was immuno-
precipitated with anti-rTFF3, anti-rIgGFccBP, or anti-rMuc2
polyclonal antibodies or preimmune serum, separated by SDS/
PAGE after the immunoprecipitates were reduced with 100 mM
DTT and detected by anti-rTFF3, anti-rIgGFccBP or anti-rMuc2
polyclonal antibodies. To block the possible covalent binding
among rTFF3, rIgGFccBP and rMuc2, the fresh rat intestinal
mucus was pretreated with 100 mM DTT; the co-immunopre-
cipitation and blotting experiment was performed as described
above.
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